News
NIH inventors have developed a new strategy of using Interleukin 24 (IL-24) to target the whole T-helper 17 cells (Th17) lineage and thus achieve improved efficacy in therapy of Th17-relevant autoimmune diseases such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. The Th17
Seven scientists in the United States and Britain who have come up with a revolutionary gene therapy cure for a rare genetic form of childhood blindness won the 2018 António Champalimaud Vision Award, a 1 million euro prize from Portugal’s Champalimaud Foundation. Among them is Michael Redmond
Scientists from the National Institute of Aging (NIA) at National Institutes of Health (NIH) in collaboration with Tawain's National Health Research Institutes and Case Western Reserve University School of Medicine worked with Peptron Inc. a Korean-based public pharmaceutical company to develop a